Compass Associates
Multi-award-winning recruitment consultancy dedicated to the independent Health, Social Care and Children's Services sectors.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Parkinson’s UK has partnered with University College London (UCL) and will invest £1m in a phase II clinical trial to investigate if the drug ondansetron can alleviate hallucinations in people with Parkinson’s disease.